Viral suppression of HIV is critical to improving the health of HIV-positive individuals, reducing HIV transmission to sexual partners and from mothers to their infants, and maintaining the effectiveness of the first-line antiretroviral therapy. Individuals with resistance to antiretroviral (ARV) drugs have substantially greater virologic failure when treated with certain treatment regimens. A cost-effective strategy is needed to detect and manage ARV-resistant HIV infections in routine HIV care and treatment programs in resource-limited settings.
A sensitive and specific oligonucleotide ligation assay (OLA), developed as a low-cost assay to detect HIV drug-resistance, can accurately quantify mutant genotypes and predict virologic failure among individuals prescribed NVP-based ART. If implemented in routine HIV care and treatment programs, the OLA could allow Kenyan clinicians to appropriately target protease inhibitor (PI)-based ART and increase rates of HIV viral suppression, potentially improving the outcome and reducing the cost of ART, and in doing so reduce the incidence of HIV infection. Furthermore, successful implementation of the OLA would give our bioengineering colleagues impetus to transform the OLA into a point of care assay.
This NIH-funded randomized controlled trial evaluated the implementation of OLA testing among HIV-infected individuals initiating ART at the Coptic Hope Center with an overall goal of improving rates of HIV viral suppression and validating whether OLA testing is cost effective in Kenya.
This study was led by Dr. Michael Chung and Dr. Lisa Frenkel of Seattle Children’s Research Institute.